Abstract
The outcome of drug induced pleurodesis has been evaluated in a non-randomised retrospective study of 67 patients with recurrent malignant pleural effusions treated during 1976-83. Fourteen died within 30 days of treatment. Of the remaining 53 patients, 26 studied during 1976-80 were treated with intrapleural mustine hydrochloride, while 27 studied during 1978-83 were treated with intrapleural Corynebacterium parvum. There was no significant difference between the groups in age, sex, or tumour type, most tumours being secondary to bronchial neoplasms. Corynebacterium parvum successfully prevented reaccumulation of the effusion in 24 (92%) patients, while mustine was effective in only 17 (65%) (p less than 0.05). Data on survival were obtained on 47 cases where a single agent was used to induce pleurodesis. In 25 patients treated with C parvum the mean survival was 251 (range 31-1143) days, compared with 119 (range 31-380) days for the 22 patients in whom mustine was used. Survival of the C parvum group was significantly greater (p less than 0.01). The difference was principally due to the greater number of long term survivors in the C parvum group, nine of this group living for more than 180 days (mean 574, range 180-1143 days) compared with only four such survivors in the mustine group (mean 263, range 193-380 days). This study confirms our initial impression that C parvum is highly effective in controlling recurrent malignant pleural effusions. The finding of unexpected long term survivors with C parvum treatment suggests that this treatment may have an additional effect on the progression of disease, a finding that merits further investigation.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Chernow B., Sahn S. A. Carcinomatous involvement of the pleura: an analysis of 96 patients. Am J Med. 1977 Nov;63(5):695–702. doi: 10.1016/0002-9343(77)90154-1. [DOI] [PubMed] [Google Scholar]
- Decker D. A., Dines D. E., Payne W. S., Bernatz P. E., Pairolero P. C. The significance of a cytologically negative pleural effusion in bronchogenic carcinoma. Chest. 1978 Dec;74(6):640–642. doi: 10.1378/chest.74.6.640. [DOI] [PubMed] [Google Scholar]
- Dhillon D. P., Spiro S. G. Malignant pleural effusions. Br J Hosp Med. 1983 Jun;29(6):506-8, 510. [PubMed] [Google Scholar]
- Jones G. R. Treatment of recurrent malignant pleural effusion by iodized talc pleurodesis. Thorax. 1969 Jan;24(1):69–73. doi: 10.1136/thx.24.1.69. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lambert C. J., Shah H. H., Urshel H. C., Jr, Paulson D. L. The treatment of malignant pleural effusions by closed trocar tube drainage. Ann Thorac Surg. 1967 Jan;3(1):1–5. doi: 10.1016/s0003-4975(10)66681-7. [DOI] [PubMed] [Google Scholar]
- Millar J. W., Hunter A. M., Horne N. W. Intrapleural immunotherapy with Corynebacterium parvum in recurrent malignant pleural effusions. Thorax. 1980 Nov;35(11):856–858. doi: 10.1136/thx.35.11.856. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Paladine W., Cunningham T. J., Sponzo R., Donavan M., Olson K., Horton J. Intracavitary bleomycin in the management of malignant effusions. Cancer. 1976 Nov;38(5):1903–1908. doi: 10.1002/1097-0142(197611)38:5<1903::aid-cncr2820380506>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]
- Rubinson R. M., Bolooki H. Intrapleural tetracycline for control of malignant pleural effusion: a preliminary report. South Med J. 1972 Jul;65(7):847–849. doi: 10.1097/00007611-197207000-00016. [DOI] [PubMed] [Google Scholar]
- Stiksa G., Korsgaard R., Simonsson B. G. Treatment of recurrent pleural effusion by pleurodesis with quinacrine. Comparison between instillation by repeated thoracenteses and by tube drainage. Scand J Respir Dis. 1979 Aug;60(4):197–205. [PubMed] [Google Scholar]